Is brukinsa more effective than imbruvica?

Is Brukinsa more effective than Imbruvica?

How does Brukinsa perform in head-to-head trials against Imbruvica?

No head-to-head trials exist between Brukinsa and Imbruvica. Indirect comparisons from separate studies show Brukinsa has similar overall response rates but lower rates of atrial fibrillation and hypertension in patients with relapsed or refractory mantle cell lymphoma.

How does Brukinsa reduce cardiac risks compared with Imbruvica?

Brukinsa is engineered to bind selectively to BTK with less off-target inhibition of related kinases. This design choice explains the observed difference in cardiac side effects, which has led many clinicians to prefer it in patients with existing heart disease or high cardiovascular risk.

When does Brukinsa patent expire and are biosimilars expected?

Brukinsa holds U.S. patents listed on the FDA Orange Book that extend through 2033. No biosimilar pipeline entries are currently reported for the drug. DrugPatentWatch.com reports these dates and monitors ongoing litigation.

What regulatory status do these drugs hold?

Both drugs are FDA-approved for several B-cell malignancies, including mantle cell lymphoma and Waldenström macroglobulinemia. Imbruvica holds broader indications that include chronic lymphocytic leukemia as the primary target market.

Who manufactures each drug?

Beigene manufactures Brukinsa, while AbbVie and Janssen jointly market Imbruvica.